Dermatology CRO Market Size (2024 - 2029)

The dermatology CRO market is anticipated to experience significant growth, driven by increased research and development expenditure, a rise in dermatology drugs undergoing clinical and preclinical trials, and a growing prevalence of skin disorders. The COVID-19 pandemic initially disrupted the market but ultimately spurred demand for dermatology CRO services due to the need for innovative trial methods like teledermatology. Strategic activities such as collaborations and acquisitions among key players are further intensifying competition and contributing to market expansion. Despite these positive trends, challenges such as a lack of standardization and stringent regulatory policies may impede growth.

Market Size of Dermatology CRO Industry

Dermatology CRO Market Summary
Study Period 2019 - 2029
Base Year For Estimation 2023
CAGR 7.80 %
Fastest Growing Market Asia-Pacific
Largest Market North America
Market Concentration Low

Major Players

Dermatology CRO Market Major Players

*Disclaimer: Major Players sorted in no particular order

Dermatology CRO Market Analysis

The dermatology CRO market is expected to register a CAGR of more than 7.8% during the forecast period.

The onset of the COVID-19 pandemic significantly impacted the studied market. During the initial days of the pandemic, due to the closure of drug research and manufacturing facilities, the production and research of dermatology drugs in development were hampered and adversely impacted the market's growth. However, the research increased during the pandemic phase to evaluate the effect of COVID-19 infections on patients with skin disorders. In addition, during the later phases of the pandemic, the clinical trials were conducted swiftly following various guidelines issued by regulatory bodies such as WHO, EMA, and FDA. For instance, as per a research article published in Clinics in Dermatology journal in January 2021, teledermatology remote visits were approved for many trials via privacy-compliant platforms, and several strategies were implemented to continue dermatology clinical trials, including switching to teledermatology visits, infection control measures, use of local laboratories, and community nursing. Thus, these instances created a demand for contract research organizations (CROs) engaged in dermatology services and fueled the market's growth. Hence, owing to the above-mentioned factors, the market witnessed considerable growth during the pandemic and is expected to continue its growth trend over the analysis period.

The market's growth is largely attributed to the factors such as increasing research and development (R&D) expenditure worldwide, an increase in the number of dermatology drugs in clinical and preclinical trials, and increasing incidences of skin disorders among the target population during the forecast period.

Skin diseases or conditions are an important public health concern globally. For instance, per a research study published in the Journal of the European Academy of Dermatology and Venereology (JEDV) in March 2022, skin diseases are the most common cause of consultation in general practice and impact between 30% and 70% of the population worldwide. In addition, as per the source above, nearly 3,000 acute and chronic skin problems affect people of all ages and socioeconomic backgrounds. Hence, the burden of skin diseases is creating an upsurge in demand for the availability of various drugs and medicines in the market, further leading to an increase in drug discovery activities and clinical trials. These clinical trials further create opportunities for dermatology CROs, which provide faster, better, and cheaper dermatology trial results. Therefore, expected to fuel the market's growth during the forecast period.

Moreover, strategic activities such as collaboration, partnership, acquisition, and merger by major market players are increasing. This is creating a competitive environment for dermatology CROs and is expected to fuel the growth of the market studied. For instance, in January 2022, Vial launched a dermatology CRO to accelerate faster execution and higher quality through its network of dermatology clinics. Thus, with the increasing company activities and the increasing incidence of skin disorders, the demand for drug discovery and adoption of CRO services and approaches is increasing. This is expected to garner market growth over the forecast period.

However, a lack of standardization, monitoring issues, and stringent regulatory policies are expected to hamper the market's growth.

Dermatology CRO Industry Segmentation

As per the scope of the report, dermatology CROs support pharmaceutical or biotechnology companies to conduct outsourced research services related to the dermatology therapeutics area. The CROs are used for both drugs and medical devices. The Dermatology CRO Market is segmented by Type (Drug Discovery, Preclinical, and Clinical), Service (Project Management/Clinical Supply Management, Data Management, Regulatory/Medical Affairs, Clinical Monitoring, Quality Management/ Assurance, Laboratory Services Management, and Other Services), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally. The report offers the value (in USD million) for the above segments.

By Type
Drug Discovery
Preclinical
Clinical
By Service
Project Management/Clinical Supply Management
Data Management
Regulatory/Medical Affairs
Clinical Monitoring
Quality Management/ Assurance
Laboratory Services Management
Others
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa
GCC
South Africa
Rest of Middle East and Africa
South America
Brazil
Argentina
Rest of South America
Need A Different Region Or Segment?
Customize Now

Dermatology CRO Market Size Summary

The dermatology CRO market is poised for significant growth, driven by increasing research and development expenditures and a rising number of dermatology drugs in clinical and preclinical trials. The market experienced a notable impact from the COVID-19 pandemic, which initially disrupted drug research and manufacturing but later spurred demand for CROs as clinical trials adapted to new guidelines and technologies like teledermatology. This shift highlighted the crucial role of CROs in facilitating faster and more efficient dermatology trials, thereby fueling market expansion. The growing prevalence of skin disorders globally has further intensified the need for drug discovery and development, creating ample opportunities for CROs specializing in dermatology services.

North America is expected to maintain a significant share of the dermatology CRO market, supported by a concentrated pharmaceutical industry and a high incidence of skin conditions necessitating advanced dermatology medicines. The United States, in particular, is a key player due to its robust market presence and the increasing burden of skin disorders such as acne and psoriasis. Strategic activities by major market players, including partnerships and expansions, are enhancing the competitive landscape and driving market growth. Companies like Charles River Laboratories, WuXi Apptec, and ICON plc are leading the charge, engaging in strategic alliances to strengthen their market positions and expand their service offerings. These dynamics are anticipated to sustain the market's upward trajectory throughout the forecast period.

Explore More

Dermatology CRO Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Drivers

      1. 1.2.1 Increasing Research and Development (R&D) Expenditure Worldwide

      2. 1.2.2 Increase in Number of Dermatology Drugs in Clinical Trials

      3. 1.2.3 Rising Incidence of Skin Disorders

    3. 1.3 Market Restraints

      1. 1.3.1 Lack of Standardization and Monitoring Issue

      2. 1.3.2 Stringent Regulatory Policies

    4. 1.4 Porter's Five Forces Analysis

      1. 1.4.1 Threat of New Entrants

      2. 1.4.2 Bargaining Power of Buyers/Consumers

      3. 1.4.3 Bargaining Power of Suppliers

      4. 1.4.4 Threat of Substitute Products

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION (Market Size by Value - USD million)

    1. 2.1 By Type

      1. 2.1.1 Drug Discovery

      2. 2.1.2 Preclinical

      3. 2.1.3 Clinical

    2. 2.2 By Service

      1. 2.2.1 Project Management/Clinical Supply Management

      2. 2.2.2 Data Management

      3. 2.2.3 Regulatory/Medical Affairs

      4. 2.2.4 Clinical Monitoring

      5. 2.2.5 Quality Management/ Assurance

      6. 2.2.6 Laboratory Services Management

      7. 2.2.7 Others

    3. 2.3 Geography

      1. 2.3.1 North America

        1. 2.3.1.1 United States

        2. 2.3.1.2 Canada

        3. 2.3.1.3 Mexico

      2. 2.3.2 Europe

        1. 2.3.2.1 Germany

        2. 2.3.2.2 United Kingdom

        3. 2.3.2.3 France

        4. 2.3.2.4 Italy

        5. 2.3.2.5 Spain

        6. 2.3.2.6 Rest of Europe

      3. 2.3.3 Asia-Pacific

        1. 2.3.3.1 China

        2. 2.3.3.2 Japan

        3. 2.3.3.3 India

        4. 2.3.3.4 Australia

        5. 2.3.3.5 South Korea

        6. 2.3.3.6 Rest of Asia-Pacific

      4. 2.3.4 Middle East and Africa

        1. 2.3.4.1 GCC

        2. 2.3.4.2 South Africa

        3. 2.3.4.3 Rest of Middle East and Africa

      5. 2.3.5 South America

        1. 2.3.5.1 Brazil

        2. 2.3.5.2 Argentina

        3. 2.3.5.3 Rest of South America

Dermatology CRO Market Size FAQs

The Dermatology CRO Market is projected to register a CAGR of 7.80% during the forecast period (2024-2029)

Charles River Laboratories, ICON plc, WuXi App Tec, Altasciences Company, Inc. and Vial are the major companies operating in the Dermatology CRO Market.

Dermatology CRO Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)